Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $42.00

Dyne Therapeutics (NASDAQ:DYNGet Free Report) had its price target boosted by analysts at Jefferies Financial Group from $36.00 to $42.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 28.72% from the company’s current price.

Other analysts have also recently issued research reports about the company. HC Wainwright lifted their price target on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday. Stifel Nicolaus boosted their price objective on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Chardan Capital reissued a “buy” rating and issued a $31.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. Morgan Stanley started coverage on Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price objective for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $40.78.

Check Out Our Latest Report on DYN

Dyne Therapeutics Stock Performance

Shares of DYN opened at $32.63 on Monday. The stock has a 50-day moving average of $26.89 and a two-hundred day moving average of $20.35. Dyne Therapeutics has a one year low of $6.40 and a one year high of $35.98. The stock has a market cap of $2.85 billion, a P/E ratio of -8.22 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting analysts’ consensus estimates of ($0.81). Analysts predict that Dyne Therapeutics will post -3.1 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 119,360 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $22.66, for a total transaction of $2,704,697.60. Following the completion of the sale, the director now directly owns 6,512,104 shares in the company, valued at approximately $147,564,276.64. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares in the company, valued at approximately $3,895,863. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 119,360 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $22.66, for a total value of $2,704,697.60. Following the transaction, the director now owns 6,512,104 shares in the company, valued at $147,564,276.64. The disclosure for this sale can be found here. Insiders sold a total of 1,183,317 shares of company stock worth $28,426,529 in the last 90 days. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Raymond James & Associates boosted its holdings in shares of Dyne Therapeutics by 22.6% during the 3rd quarter. Raymond James & Associates now owns 88,238 shares of the company’s stock worth $791,000 after purchasing an additional 16,240 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Dyne Therapeutics by 4.8% in the third quarter. Bank of New York Mellon Corp now owns 157,443 shares of the company’s stock valued at $1,411,000 after acquiring an additional 7,196 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock valued at $75,000 after acquiring an additional 3,092 shares during the last quarter. TD Asset Management Inc acquired a new position in Dyne Therapeutics in the third quarter valued at approximately $206,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock valued at $83,000 after acquiring an additional 4,552 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Featured Articles

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.